Checkpoint Therapeutics Inc
NASDAQ:CKPT

Watchlist Manager
Checkpoint Therapeutics Inc Logo
Checkpoint Therapeutics Inc
NASDAQ:CKPT
Watchlist
Price: 4.26 USD 0.71%
Market Cap: 370.7m USD

Operating Margin

-137 009.8%
Current
Declining
by 80 073.6%
vs 3-y average of -56 936.1%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-137 009.8%
=
Operating Income
$-56.2m
/
Revenue
$41k

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-137 009.8%
=
Operating Income
$-56.2m
/
Revenue
$41k

Peer Comparison

Country Company Market Cap Operating
Margin
US
Checkpoint Therapeutics Inc
NASDAQ:CKPT
356.8m USD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
378.8B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
177.8B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
155.1B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
112.1B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
77.2B USD
Loading...
AU
CSL Ltd
ASX:CSL
85.6B AUD
Loading...
NL
argenx SE
XBRU:ARGX
40.7B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
47.3B USD
Loading...
No Stocks Found

Market Distribution

Lower than 99% of companies in the United States of America
Percentile
1st
Based on 14 112 companies
1st percentile
-137 009.8%
Low
-4 087 900% — -5.1%
Typical Range
-5.1% — 14.8%
High
14.8% — 1 032 600%
Distribution Statistics
the United States of America
Min -4 087 900%
30th Percentile -5.1%
Median 6%
70th Percentile 14.8%
Max 1 032 600%

Checkpoint Therapeutics Inc
Glance View

Market Cap
370.7m USD
Industry
Biotechnology

Checkpoint Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company is headquartered in New York City, New York and currently employs 14 full-time employees. The company went IPO on 2016-11-02. The firm is evaluating its lead antibody product candidate, cosibelimab, which is an anti-programmed death-ligand 1 (PD-L1) antibody licensed from the Dana-Farber Cancer Institute (Dana-Farber) in an ongoing global, open-label, multicohort Phase I clinical trial in checkpoint therapy-naive patients with selected recurrent or metastatic cancers, including ongoing cohorts in locally advanced and metastatic cutaneous squamous cell carcinoma (CSCC) intended to support one or more applications for marketing approval. In addition, it is evaluating its lead small-molecule, targeted anti-cancer agent, CK-101, which is an epidermal growth factor receptor (EGFR) inhibitor as a treatment for patients with EGFR mutation-positive non-small cell lung cancer (NSCLC).

CKPT Intrinsic Value
Not Available
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
-137 009.8%
=
Operating Income
$-56.2m
/
Revenue
$41k
What is Checkpoint Therapeutics Inc's current Operating Margin?

The current Operating Margin for Checkpoint Therapeutics Inc is -137 009.8%, which is below its 3-year median of -56 936.1%.

How has Operating Margin changed over time?

Over the last 3 years, Checkpoint Therapeutics Inc’s Operating Margin has decreased from -21 007.4% to -137 009.8%. During this period, it reached a low of -137 009.8% on Jan 31, 2025 and a high of -21 007.4% on Dec 1, 2021.

Back to Top